According tomedia reports, one of the biggest killers on Earth is a bacteria that humans have been fighting for thousands of years — tuberculosis, or TB. Vaccination of TB has proved very difficult, and the effectiveness of the vaccine has historically been very low. However, that may be about to change as BCG test researchers have discovered a way to make it more effective.
Scientists have produced some pretty surprising results in vaccine trials in rhesus monkeys, according to a new report by the U.S. National Institutes of Health. It turns out that maximizing the effectiveness of the vaccine may be as easy as targeting veins.
Typically, the vaccine is injected under the skin. This seems to be preventing the best results of the vaccine. In testing the immune pathway, the researchers found that a certain dose of the vaccine through intravenous injectionrather rather than intracutaneous injection scanted significantly improved the vaccine’s effectiveness.
To understand the differences between different types of vaccination, the researchers vaccinated BGC to different groups of monkeys in different ways. The monkeys were injected with the vaccine through subcutaneous injections, intravenous injections and aerosol injections.
The scientists then assessed the subjects’ immune response to blood and lung fluid satout within 24 weeks of vaccination, and finally showed that the monkeys who were intravenously had the highest tolerance for their blood and lung T cells.
To further the study, the researchers exposed the monkeys to TB six months after they were vaccinated. As a result, the vast majority of monkeys who were given intravenous lyno sin sbs showed high levels of protection against bacteria, and they were more resistant to infection than the other two groups.
Looking ahead, the researchers say the evidence suggests that TB immunization in the human body may be worth reconsidering and that intravenous testing may be necessary.